Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 23, Issue 11, 2005, Pages 2521-2533

  Tabernero, Josep ^a   Rojo, Fredy ^a   Marimón, Irene ^a   Voi, Maurizio ^a   Albanell, Joan ^a   Guix, Marta ^a   Vázquez, Federico ^a   Carulla, Joan ^a   Cooper, Michael ^a   Andreu, Jordi ^a   Van Vreckem, Anne ^a   Bellmunt, Joaquim ^a   Manne, Veeraswamy ^a   Manning, James A ^a   Garrido, Carmen ^a   Felip, Enriqueta ^a   Del Campo, Josep Maria ^a   García, Mónica ^a   Valverde, Sonia ^a   Baselga, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; 7-CYANO-2,3,4,5-TETRAHYDRO-1-(1H-IMIDAZOL-4-YLMETHYL)-3-(PHENYLMETHYL)-4-(2-THIENYLSULFONYL)-1H-1,4-BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; FARNESYL TRANS TRANSFERASE; IMIDAZOLE DERIVATIVE; TRANSFERASE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CANCER; VOMITING; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM; SIGNAL TRANSDUCTION;

ADULT; AGED; ALKYL AND ARYL TRANSFERASES; APOPTOSIS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 20244375849     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.00.398     Document Type: Article

References (66)

1. Bos JL: ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
2. Barbacid M: ras genes. Annu Rev Biochem 56:779-827, 1987
3. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 366:643-654, 1993
4. Albanell J, Rojo F, Sonnicchsen D, et al: Elevated farnesyltransferase activity in chemonaive breast cancer tissue as compared to normal surrounding tissue. Proc Am Soc Cancer Res 42:489, 2001 (abstr 2634)
5. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17:3631-3652, 1999
6. Gibbs JB, Graham SL, Hartman GD, et al: Famesyltransferase inhibitors versus Ras inhibitors. Curr Opin Chem Biol 1:197-203, 1997
7. Gibbs JB: Ras C-terminal processing enzymes-new drug targets? Cell 65:1-4, 1991
8. Gibbs JB, Oliff A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37:143-166, 1997
9. Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras? Biochim Biophys Acta 1333:F51-F71, 1997
10. Lerner EC, Hamilton AD, Sebti SM: Inhibition of Ras prenylation: A signaling target for novel anti-cancer drug design. Anticancer Drug Des 12:229-238, 1997
11. Tamanoi F: Inhibitors of Ras farnesyltransferases. Trends Biochem Sci 18:349-353, 1993
12. James GL, Goldstein JL, Brown MS, et al: Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260:1937-1942, 1993
13. Kohl NE, Mosser SD, deSolms SJ, et al: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934-1937, 1993
14. Kohl NE, Omer CA, Conner MW, et al: Inhibition of farnesyltransferase Induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1:792-797, 1995
15. Nagasu T, Yoshimatsu K, Rowell C, et al: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55:5310-5314, 1995
16. Manne V, Yan N, Carboni JM, et al: Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells. Oncogene 10:1763-1779, 1995
17. Bishop WR, Bond R, Petrin J, et al: Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells. J Biol Chem 270:30611-30618, 1995
18. Lebowitz PF, Prendergast GC: Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho. Oncogene 17:1439-1445, 1998
19. Du W, Lebowitz PF, Prendergast GC: Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 19:1831-1840, 1999
20. Du W, Liu A, Prendergast GC: Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 59:4208-4212, 1999
21. Lebowitz PF, Davide JP, Prendergast GC: Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 15:6613-6622, 1995
22. Lebowitz PF, Sakamuro D, Prendergast GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 57:708-713, 1997
23. Law BK, Norgaard P, Moses HL: Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli. J Biol Chem 275:10796-10801, 2000
24. Jiang K, Coppola D, Crespo NC, et al: The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 20:139-148, 2000
25. Prendergast GC, Khosravi-Far R, Solski PA, et al: Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 10:2289-2296, 1995
26. Prendergast GC, Davide JP, deSolms SJ, et al: Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14:4193-4202, 1994
27. Lerner EC, Zhang TT, Knowles DB, et al: Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15:1283-1288, 1997
28. Whyte DB, Kirschmeier P, Hockenberry TN, et al: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459-14464, 1997
29. Rowell CA, Kowalczyk JJ, Lewis MD, et al: Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 272:14093-14097, 1997
30. Sun J, Qian Y, Hamilton AD, et al: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55:4243-4247, 1995
31. Suzuki N, Del Villar K, Tamanoi F: Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc Natl Acad Sci U S A 95:10499-10504, 1998
32. Suzuki N, Urano J, Tamanoi F: Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci U S A 95:15356-15361, 1998
33. Prendergast GC: Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol 12:166-173, 2000
34. Sebti SM, Hamilton AD: Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol Ther 74:103-114, 1997
35. Lobell RB, Kohl NE: Pre-clinical development of farnesyltransferase inhibitors. Cancer Metastasis Rev 17:203-210, 1998
36. Ashar HR, Armstrong L, James LJ, et al: Biological effects and mechanism of action of farnesyl transferase inhibitors. Chem Res Toxicol 13:949-952, 2000
37. Fiordalisi JJ, Johnson RL, 2nd, Weinbaum CA, et al: High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors. J Biol Chem 278:41718-41727, 2003
38. Hunt JT, Ding CZ, Batorsky R, et al: Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl) -1 H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem 43:3587-3595, 2000
39. Manne V, Lee FY, Bol DK, et al: Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models. Cancer Res 64:3974-3980, 2004
40. Rose WC, Lee FY, Fairchild CR, et al: Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res 61:7507-7517, 2001
41. Lee FY, Arico-Gray M, Camuso A, et al: The pro-apoptotic FT inhibitor BMS-214662 produced synergistic effects in combination with chemotherapy with antiproliferative cytotoxic agents. Proceedings of the 2001 AACR-NCI-EORTC International Conference:82, 2001 (abstr 401)
42. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 103:239-252, 2000
43. Ryan DP, Eder JP, Jr., Puchlaski T, et al: Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 10:2222-2230, 2004
44. Lacey LF, Keene ON, Pritchard JF, et al: Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed? J Biopharm Stat 7:171-178, 1997
45. Mizuta E, Tsubotani A: Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull (Tokyo) 33:1620-1632, 1985
46. Lam FC, Hung CT, Perrier DG: Estimation of variance for harmonic mean half-lives. J Pharm Sci 74:229-231, 1985
47. Manne V, Roberts D, Tobin A, et al: Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc Natl Acad Sci USA 87:7541-7545, 1990
48. Albanell J, Rojo F, Averbuch S, et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124, 2002
49. Matar P, Rojo F, Cassia R, et al: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 10:6487-6501, 2004
50. Rohn TT, Rissman RA, Davis MC, et al: Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 11:341-354, 2002
51. Woenckhaus C, Giebel J, Failing K, et al: Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? J Pathol 201:278-287, 2003
52. Adjei AA, Erlichman C, Davis JN, et al: A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 60:1871-1877, 2000
53. Karp JE, Lancet JE, Kaufmann SH, et al: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 97:3361-3369, 2001
54. Chun KH, Lee HY, Hassan K, et al: Implication of protein kinase B/Akt and Bcl-2/ Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res 63:4796-4800, 2003
55. Mizukami Y, Ura H, Obara T, et al: Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells. Biochem Biophys Res Commun 288:198-204, 2001
56. Tabernero J, Rojo F, Jimenez E, et al: A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour infusion EMD72000, a humanized anti-epider-mal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 22:192, 2003 (abstr 770)
57. Rojo F, Tabernero J, Van Cutsem E, et al: Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD1839). Proc Am Soc Clin Oncol 22:191, 2003 (abstr 764)
58. Baselga J, Albanell J, Ruiz A, et al: Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 22:7, 2003 (abstr 24)
59. Baselga J: Skin as a surrogate tissue for pharmacodynamic end points: Is it deep enough? Clin Cancer Res 9:2389-2390, 2003
60. Arteaga CL, Baselga J: Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them? Cancer Cell 5:525-531, 2004
61. Sonnichsen D, Damle B, Manning J, et al: Pharmocokinetics (PK) and pharmacodynamics (PD) of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 19:178a, 2000 (abstr 691)
62. Kim KB, Shin DM, Summey CC, et al: Phase I study of farnesyl transferase inhibitor, BMS-214662 in solid tumors. Proc Am Soc Clin Oncol 20:79a, 2001 (abstr 313)
63. Camacho LH, Soignet SL, Pezzulli S, et al: Dose escalation of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors. Proc Am Soc Clin Oncol 20:79a, 2001 (abstr 311)
64. Mackay HJ, Hoekstra R, Eskens FA, et al: A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res 10:2636-2644, 2004
65. Bailey HH, Marnocha R, Arzoomanian R, et al: Phase I trial of weekly paclitaxel and BMS214662 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 20:79a, 2001 (abstr 314)
66. Dy GK, Bruzek LM, Croghan GA, et al: A phase I trial of the farnesyltransferase (FT) inhibitor, BMS-214662 (B) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced cancer. Proc Am Soc Clin Oncol 23:211, 2004 (abstr 3066)